Image

Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU)

Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU)

Recruiting
18-50 years
Female
Phase N/A

Powered by AI

Overview

MRI-guided high intensity focused ultrasound (MRI-HIFU) has been proven to be a safe and effective method in treating uterine fibroids and also adenomyosis. However, systematic studies on the effect of this treatment on factors affecting fertility are still lacking. Also quite little is known about body's systemic response to MRI-HIFU. Thus the aim of this study is to obtain more information on the systemic response of the body to the HIFU-treatment when treating non-malignant disease as well as to study the effect of MRI-HIFU on factors affecting fertility. Women with symptomatic uterine fibroids or adenomyosis suitable for MRI-HIFU treatment are recruited to this study. The severity of symptoms will be assessed with UFS-QoL and the same questionnaire will also be used in follow-up 3, 6 and 12 months after treatment. Blood, urine and endometrium samples will be collected pre- and postoperatively and during follow-up 3, 6 and 12 months after the treatment. From these samples detailed analysis of the immunological, inflammatory and hormonal response will be performed. As this is the first study in Finland of treating uterine fibroids and adenomyosis using MRI-HIFU, also a report about the efficacy of the MRI-HIFU in treating the uterine disorders will be published, and a key tool in assessing the treatment outcome would be the UFS-QoL questionnaire.

Also new methods for improving patient selection as well as treatment efficacy will be evaluated in this study.

Eligibility

Inclusion Criteria:

  • BMI < 35
  • Premenopausal
  • Uterine size <20 gw
  • Willingness to participate to the research
  • Uterine fibroids with typical symptoms
  • Maximum of 4 treated fibroids
  • Dominant fibroid >2.5cm
  • >50% of the fibroid is treatable

Exclusion criteria

  • Unspecified pelvic tumours or ovarian masses, PID
  • Major corrective surgery to uterus (simple myomectomy excluded)
  • Major uterine anomalies
  • Unability to calculate the volume of uterine fibroids
  • Marked uterine calcification
  • Marked scarring of the lower abdomen
  • Suspicion of malignancy
  • Marked general health problem contraindicating MRI
  • Claustrophobia

Study details
    Uterine Fibroids
    Adenomyosis

NCT02914704

Turku University Hospital

27 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.